Researchers from Massachusetts General Hospital have identified peripheral neuropathy in more than half of a group of long COVID patients, suggesting that it may be a mechanism that contributes to multiple, seemingly disparate, long COVID symptoms.
Visby Medical Inc. reeled in more than $100 million in a series E round led by Ping An Voyager Partners. The funds will be used to scale production capacity of Visby’s instrument-free, single-use real-time polymerase chain reaction (RT-PCR) platform from tens to hundreds of thousands of tests per month.
Two years ago, BioWorld reported on 30 therapeutics and vaccines in development for COVID-19, about 3,000 people had died from the disease, and societal lockdowns began. Today, therapeutics and vaccines have ballooned to 1,048, deaths are at 6 million, and the world remains on edge due to highly transmissible variants and breakthrough infections. One thing remains the same: Scientists still do not know where the SARS-CoV-2 virus originated.
The U.S. is making strides in addressing the drug and device supply chain vulnerabilities revealed by the COVID-19 pandemic, but there’s still a lot of work to do to reduce dependance on sole source suppliers and foreign manufacturing, according to a new Health and Human Services (HHS) report.
SK Bioscience Ltd. is developing a vaccine intended to simultaneously immunize people against the flu and COVID-19. It is the first vaccine of its type to be developed in South Korea and will use the technology from Skycellflu, a cell-cultivated influenza vaccine developed by the Seongnam-si, South Korea-based company.
RSS
